Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
Cytokinetics has launched MYQORZO (aficamten) commercially in Germany, marking the first European availability of its approved cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM). The launch follows European Commission approval in February 2026, which was based on the pivotal Phase 3 SEQUOIA-HCM trial showing robust efficacy and safety. This expansion into the EU complements existing approvals in the U.S.
Key figures
- Drug Name
- MYQORZO (aficamten)
- Trial name
- SEQUOIA-HCM
- Pvo2 improvement
- 1.76 mL/kg/min
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.